Jefferies Financial Group Inc. Acquires 65,395 Shares of CG Oncology, Inc. $CGON

Jefferies Financial Group Inc. increased its stake in shares of CG Oncology, Inc. (NASDAQ:CGON) by 8.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 835,342 shares of the company’s stock after buying an additional 65,395 shares during the period. CG Oncology accounts for approximately 0.4% of Jefferies Financial Group Inc.’s holdings, making the stock its 24th biggest holding. Jefferies Financial Group Inc.’s holdings in CG Oncology were worth $59,217,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in CGON. WINTON GROUP Ltd bought a new position in shares of CG Oncology in the second quarter worth about $718,000. Legal & General Group Plc acquired a new position in shares of CG Oncology during the second quarter worth approximately $2,846,000. Jupiter Topco LLC acquired a new position in shares of CG Oncology during the second quarter worth approximately $1,634,000. The Manufacturers Life Insurance Company acquired a new position in shares of CG Oncology during the second quarter worth approximately $5,766,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of CG Oncology during the second quarter valued at approximately $16,584,000. Institutional investors own 26.56% of the company’s stock.

CG Oncology News Summary

Here’s some of the latest news about CGON:

• Positive Sentiment: CG Oncology’s third-quarter loss was narrower than analysts expected, and revenue exceeded estimates. HC Wainwright also maintained a Buy rating and a $100 price target, raising its FY2026 and Q4 2026 earnings forecasts. What CG Oncology’s Third Quarter Earnings Means For Shareholders
• Neutral Sentiment: A short-interest update reported zero shares sold short and a zero-day days-to-cover ratio, despite describing short interest as having increased. The figures do not indicate a meaningful short position.
• Negative Sentiment: HC Wainwright lowered its earnings forecasts for FY2027, FY2028 and FY2030, suggesting it expects a slower path to profitability farther out, although it kept its Buy rating and $100 target.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on CGON shares. Royal Bank Of Canada lowered their price target on shares of CG Oncology from $81.00 to $79.00 and set an “outperform” rating for the company in a report on Friday, August 7th. HC Wainwright reaffirmed a “buy” rating and set a $100.00 price objective on shares of CG Oncology in a report on Wednesday, July 29th. Truist Financial upped their price objective on CG Oncology from $82.00 to $85.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Wall Street Zen upgraded CG Oncology from a “strong sell” rating to a “sell” rating in a research report on Saturday, November 7th. Finally, Wedbush lifted their target price on CG Oncology from $80.00 to $84.00 and gave the company an “outperform” rating in a research note on Friday, November 6th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, CG Oncology presently has an average rating of “Moderate Buy” and a consensus price target of $88.11.

Insiders Place Their Bets

In other CG Oncology news, Director Leonard E. Post sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $62.06, for a total value of $62,060.00. Following the transaction, the director directly owned 1,000 shares of the company’s stock, valued at approximately $62,060. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 3,000 shares of company stock valued at $209,580 in the last quarter. Corporate insiders own 4.80% of the company’s stock.

CG Oncology Trading Down 0.0%

Shares of NASDAQ CGON opened at $72.61 on Thursday. The firm has a market capitalization of $6.49 billion, a PE ratio of -26.31 and a beta of 0.35. CG Oncology, Inc. has a 1 year low of $37.01 and a 1 year high of $80.97. The firm’s 50-day moving average is $68.13 and its 200-day moving average is $66.36.

CG Oncology (NASDAQ:CGON) last issued its quarterly earnings results on Friday, November 6th. The company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.19. The company had revenue of $1.60 million during the quarter, compared to analysts’ expectations of $0.55 million. CG Oncology had a negative net margin of 3,851.09% and a negative return on equity of 24.58%. As a group, equities research analysts anticipate that CG Oncology, Inc. will post -3.03 earnings per share for the current fiscal year.

About CG Oncology

CG Oncology is a clinical-stage biotechnology company focused on developing treatments for bladder cancer. Based in Irvine, California, the company’s research centers on therapies delivered directly into the bladder. Its lead investigational therapy, cretostimogene grenadenorepvec (formerly CG0070), is an oncolytic immunotherapy being developed for non-muscle-invasive bladder cancer, including disease that has not responded to Bacillus Calmette-Guérin (BCG) treatment. The modified virus is designed to target cancer cells and stimulate an immune response.